Ayala Pharmaceuticals Inc (ADXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 01-2022 | 10-2021 | 07-2021 | 04-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,953 | -365 | N/A | -12,418 | -9,084 |
| Depreciation Amortization | 30 | 199 | N/A | 986 | 847 |
| Accounts receivable | -638 | N/A | N/A | N/A | -1,375 |
| Accounts payable and accrued liabilities | -651 | N/A | N/A | N/A | N/A |
| Other Working Capital | -704 | -196 | N/A | -382 | -1,560 |
| Other Operating Activity | 1,932 | -3,776 | 0 | 111 | 2,272 |
| Operating Cash Flow | $-9,984 | $-4,138 | $N/A | $-11,703 | $-8,900 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | 219 | 214 |
| Purchase Sale Intangibles | N/A | -58 | N/A | -323 | -268 |
| Other Investing Activity | 0 | -58 | 0 | -323 | -268 |
| Investing Cash Flow | $N/A | $-58 | $N/A | $-104 | $-54 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 44 | N/A | N/A | 28,115 | 31,886 |
| Other Financing Activity | 0 | 4,312 | 0 | 3,771 | 0 |
| Financing Cash Flow | $44 | $4,312 | $N/A | $31,886 | $31,886 |
| Beginning Cash Position | 37,339 | 41,614 | N/A | 25,178 | 25,178 |
| End Cash Position | 27,399 | 41,730 | N/A | 45,257 | 48,110 |
| Net Cash Flow | $-9,940 | $116 | $N/A | $20,079 | $22,932 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,984 | -4,138 | N/A | -11,703 | -8,900 |
| Free Cash Flow | -9,984 | -4,138 | 0 | -11,703 | -8,900 |